Standard BioTools Inc.

NasdaqGS:LAB Stock Report

Market Cap: US$979.1m

Standard BioTools Balance Sheet Health

Financial Health criteria checks 5/6

Standard BioTools has a total shareholder equity of $163.2M and total debt of $63.5M, which brings its debt-to-equity ratio to 38.9%. Its total assets and total liabilities are $323.1M and $159.9M respectively.

Key information

38.9%

Debt to equity ratio

US$63.51m

Debt

Interest coverage ration/a
CashUS$114.90m
EquityUS$163.20m
Total liabilitiesUS$159.87m
Total assetsUS$323.07m

Recent financial health updates

Recent updates

Is It Time To Consider Buying Standard BioTools Inc. (NASDAQ:LAB)?

Apr 09
Is It Time To Consider Buying Standard BioTools Inc. (NASDAQ:LAB)?

Estimating The Fair Value Of Standard BioTools Inc. (NASDAQ:LAB)

Mar 06
Estimating The Fair Value Of Standard BioTools Inc. (NASDAQ:LAB)

Standard BioTools Inc.'s (NASDAQ:LAB) P/S Still Appears To Be Reasonable

Feb 17
Standard BioTools Inc.'s (NASDAQ:LAB) P/S Still Appears To Be Reasonable

Health Check: How Prudently Does Standard BioTools (NASDAQ:LAB) Use Debt?

Jan 12
Health Check: How Prudently Does Standard BioTools (NASDAQ:LAB) Use Debt?

Is Standard BioTools (NASDAQ:LAB) A Risky Investment?

Aug 13
Is Standard BioTools (NASDAQ:LAB) A Risky Investment?

Fluidigm Corporation: Investment Opportunity

Jan 26

Does Fluidigm (NASDAQ:FLDM) Have A Healthy Balance Sheet?

Dec 15
Does Fluidigm (NASDAQ:FLDM) Have A Healthy Balance Sheet?

Is Fluidigm (NASDAQ:FLDM) A Risky Investment?

Jul 27
Is Fluidigm (NASDAQ:FLDM) A Risky Investment?

Fluidigm Corporation: Discounted Life Sciences Instrument Developer Offers Compelling Entry Point

Jun 20

Fluidigm gains after report that activist takes 11% stake, may push for unit sale

May 11

Fluidigm Corporation 2021 Q1 - Results - Earnings Call Presentation

May 07

Financial Position Analysis

Short Term Liabilities: LAB's short term assets ($158.2M) exceed its short term liabilities ($109.3M).

Long Term Liabilities: LAB's short term assets ($158.2M) exceed its long term liabilities ($50.5M).


Debt to Equity History and Analysis

Debt Level: LAB has more cash than its total debt.

Reducing Debt: LAB's debt to equity ratio has reduced from 238.6% to 38.9% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LAB has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: LAB has less than a year of cash runway if free cash flow continues to reduce at historical rates of 19.8% each year


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.